Material and Methods:
Fifteen patients with ≥T2b disease who were due to receive RT (60 Gy in 20 fractions) were recruited after 3 months of NA-HT. Patients underwent three 1.5 T MRI examinations: post NA-HT (one week prior to RT), at the end of the third week of treatment, and eight weeks after RT completion. The imaging protocol included T2 weighted and diffusion weighted imaging, acquired using the cardiac coil (EPI with TR/TE 8000/70 ms, b = 100, 400, 800 s/mm²). ADC maps were processed offline (ADCmap for Osirix). Normal central gland (CG), peripheral zone (PZ) and tumour were outlined on T2w images by a radiologist expert in prostate MRI, with pre-NA-HT imaging (T2w and DWI) available in 12 patients to aid identification. If disease was not clearly visible, clinical findings and biopsy results were used to aid delineation. CG, PZ and tumour regions were transferred to the ADC maps and median values extracted along with interquartile ranges. A Mann-Whitney U test was used to analyse differences between tumour and normal tissue regions at the three time points.
Results: 13 patients completed all scans, 2 patients missed 1 and 2 scans respectively. After NA-HT, there was a significant difference between median tumour and PZ (p= 0.009) and tumour and CG (p=0.002) (median values plotted in figure 1) . At the other time points, there was no difference between tumour and normal tissue ADCs.
Conclusion:
The ADC values display a similar pattern to that seen in previous studies for patients receiving RT alone. The difference between tumour and normal tissue was smaller at baseline than has been seen in other work without NA-HT. This may be due to a reduction in normal tissue ADC during induction therapy, whilst tumour ADC values could have increased due to tumour shrinkage. Variation in imaging protocol for ADC measurement compared to previous studies may also play a role. The reduced magnitude of changes in tumour ADC seen during RT after NA-HT may make its use as a predictive tool for treatment response more challenging in this group of patients.
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